Loading organizations...
§ Private Profile · 3 Lagoon Dr Ste 160, Redwood City, California, 94065, United States
XWPharma 凯瑞康宁 is a company.
XWPharma 凯瑞康宁 has raised $57.5M across 2 funding rounds.
Key people at XWPharma 凯瑞康宁.
XWPharma 凯瑞康宁 has raised $57.5M in total across 2 funding rounds.
XWPharma is a clinical-stage biopharmaceutical company developing central nervous system (CNS) therapeutics. It employs novel platform chemistry and a proprietary drug discovery methodology centered on time-regulated neurobiology. The company's pipeline includes Valilxoybate, a GABA B agonist for narcolepsy and Parkinson’s disease non-motor symptoms, and XW10508, a glutamatergic NMDA antagonist and AMPA activator addressing major depressive disorder and chronic pain.
Founded by Dr. Jia-Ning Xiang, who also serves as Chief Scientific Officer, XWPharma's inception stems from his extensive medicinal chemistry experience. His background includes leadership roles at GlaxoSmithKline Neuroscience Center, XenoPort, and SmithKline Beecham, where he contributed to multiple clinical-stage compounds for CNS disorders. This expertise underpins the company's proprietary approach to drug development.
XWPharma aims to provide hope for patients facing neurodegenerative and psychiatric disorders with unmet needs. The company's vision is to deliver best-in-class novel therapeutics that relieve suffering by achieving superior efficacy and overcoming limitations of existing treatments. It focuses on de-risking programs early to bring impactful medicines to those in need.
Key people at XWPharma 凯瑞康宁.
XWPharma 凯瑞康宁 has raised $57.5M in total across 2 funding rounds.
XWPharma 凯瑞康宁's investors include Hongdao Capital, Huachuang Yida, Johnson & Johnson Innovation, KTB Network, Sany Innovation Investment, WuXi AppTec, Zhongjinghe Group, Elements Capital, WI Harper Group, KPCB China, WuXi Venture.
XWPharma 凯瑞康宁 has raised $57.5M across 2 funding rounds. Most recently, it raised $40.0M XW Laboratories - Series C in September 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 20, 2020 | $40M Series C | — | Hongdao Capital, Huachuang Yida, Johnson & Johnson Innovation, KTB Network, Sany Innovation Investment, WuXi AppTec, Zhongjinghe Group | Announced |
| Sep 20, 2017 | $17.5M Series B | Elements Capital, WI Harper Group | Johnson & Johnson Innovation, KPCB China, KTB Network, Wuxi Venture | Announced |
# XWPharma (凯瑞康宁) Overview
XWPharma is a clinical-stage biopharmaceutical company focused on discovering and developing central nervous system (CNS) therapeutics for neurological and neuropsychiatric disorders.[1] The company leverages proprietary platform chemistry and clinically validated mechanisms of action to create novel drug candidates with optimized pharmacokinetics.[3] XWPharma operates across multiple regions, with offices in the United States, China, and Taiwan, and has raised approximately $63 million in Series C funding.[1][2]
XWPharma addresses unmet medical needs in debilitating neurological diseases by developing potential first- and best-in-class medicines with differentiated features.[3] The company's pipeline includes investigational therapies targeting conditions such as narcolepsy, non-motor symptoms of Parkinson's disease, major depressive disorder, and chronic pain, with specific drug candidates including XW10172 for excessive daytime sleepiness.[1] As a clinical-stage company, XWPharma is advancing its CNS therapeutics pipeline while preparing for future stages of growth and development, having recently expanded its clinical development and commercialization capabilities in the United States.[2]
XWPharma was founded in 2014 and was formerly known as XW Laboratories.[1][4] The company was established by Jia-Ning Xiang, PhD, who has served as Chief Scientific Officer since April 2020 and Member of the Board of Directors since the company's founding in February 2014.[5] Dr. Xiang brings substantial experience from his previous roles, including Chief Development Officer at ARYx Therapeutics and Vice President of Clinical Development at XenoPort, where he led the clinical development of gabapentin enacarbil to FDA approval for neuropathic pain and Willis-Ekbom disease.[5]
The company's leadership team includes experienced biopharmaceutical entrepreneurs. Dr. Robbins, for example, has co-founded multiple early-stage biopharmaceutical companies including NeurogesX (acquired by Acorda Therapeutics), Limerick BioPharma, and Labrys Biologics (acquired by TEVA in 2014), bringing deep expertise in building companies from inception through clinical development and acquisition.[5]
XWPharma operates within a competitive but growing market for CNS therapeutics. The excessive daytime sleepiness pipeline alone includes 10+ key companies developing 12+ treatment therapies globally, with XWPharma positioned alongside competitors such as Takeda Pharmaceuticals, Avadel Pharmaceuticals, and Balance Therapeutics.[1] The company's focus on time-regulated neurobiology represents a differentiated approach within this crowded space, potentially offering advantages in efficacy and tolerability.
The timing is favorable for CNS drug development, as neurological and neuropsychiatric disorders represent significant unmet medical needs with substantial patient populations. XWPharma's expansion into the U.S. market and investment in clinical development infrastructure suggest confidence in advancing its pipeline toward regulatory milestones.
XWPharma is positioned at a critical inflection point. With $63 million raised and a clinical-stage pipeline, the company is likely focused on advancing lead candidates through Phase 2 and Phase 3 clinical trials over the next 2-3 years. Success in these trials could unlock significant value and attract larger pharmaceutical partners or acquirers, following the precedent set by earlier exits of its leadership team's previous ventures.
The company's strength lies in its experienced management, differentiated chemistry platform, and focus on high-need CNS indications. Key risks include the inherent uncertainty of clinical development, competitive pressure from larger pharmaceutical companies, and the capital intensity required to bring drugs to market. As XWPharma advances its pipeline, its ability to demonstrate clinical efficacy and secure partnerships or additional funding will determine its trajectory in the competitive CNS therapeutics landscape.
